Our current pipeline aims to disrupt existing treatment paradigms by combining new molecular entities with best-in-class potential and a leading-edge platform targeting medical dermatology, autoimmune and neuroinflammatory diseases.
Pipeline
| Program | Indication(s) | Discovery | Preclinical | Phase I | Phase II | Phase III | Approved | Next Milestone | |
|---|---|---|---|---|---|---|---|---|---|
 |
Sofpironium Bromide Retrometabolic Anticholinergic |
Primary Axillary Hyperhidrosis |
NDA Submission: Mid-2022 |
||||||
Commercialized in Japan: ECCLOCK® Gel 5%
|
|||||||||
| Primary Palmoplantar Hyperhidrosis |
|
Ph1 Data | |||||||
 |
BBI-02 DYRK1A inhibitor |
|
Ph1 Initiation: 2022 Ph1 Results: End-2022 |
||||||
|
BBI-03 DYRK1A inhibitor |
|
Formulation Development: 2022 |
||||||
|
Next Generation DYRK1A inhibitor |
Neuroinflammatory & Other Diseases |
Lead Selection: 2022 |
||||||
 Topical  Oral
|
|||||||||
Click on image to enlarge it